# Retro Biosciences

backed by Sam Altman, closed a funding round at a $1.8 billion valuation in May 2026, working on iPSC-derived, AAV and small-molecule therapies with the help of AI models.

Source: https://en.bioecon.ru/companies/retro-biosciences/
Updated: 2026-07-20

- Country: United States

## Technologies

- [Partial epigenetic reprogramming](https://en.bioecon.ru/technology/partial-epigenetic-reprogramming/)